Astrazeneca plc ADR (AZN) Beta Value: Understanding the Market Risk
The price-to-earnings ratio for Astrazeneca plc ADR (NASDAQ: AZN) is above average at 37.05x. The 36-month beta value for AZN is also noteworthy at 0.49.
The price-to-earnings ratio for Astrazeneca plc ADR (NASDAQ: AZN) is above average at 37.05x. The 36-month beta value for AZN is also noteworthy at 0.49.
The stock of Astrazeneca plc ADR (AZN) has gone up by 2.02% for the week, with a 5.94% rise in the past month and a
The stock price of Astrazeneca plc ADR (NASDAQ: AZN) has dropped by -0.75 compared to previous close of 69.45. Despite this, the company has seen
Astrazeneca plc ADR (NASDAQ: AZN) has seen a rise in its stock price by 0.37 in relation to its previous close of 67.45. However, the
The stock of Astrazeneca plc ADR (NASDAQ: AZN) has decreased by -0.74 when compared to last closing price of 67.75.Despite this, the company has seen
The use of the AZD 1222 vaccine against COVID-19 produced by AstraZeneca plc (AZN) for emergencies has been authorized this month by the Indian government
© 2024, Powered by Smart TechOne
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.